CogMol: Target-Specific and Selective Drug Design for COVID-19 Using Deep Generative Models
Vijil Chenthamarakshan, Payel Das, Samuel C. Hoffman, Hendrik Strobelt, Inkit Padhi, Kar Wai Lim, Benjamin Hoover, Matteo Manica, Jannis Born, Teodoro Laino, Aleksandra Mojsilovic
摘要
The novel nature of SARS-CoV-2 calls for the development of efficient de novo drug design approaches. In this study, we propose an end-to-end framework, named CogMol (Controlled Generation of Molecules), for designing new drug-like small molecules targeting novel viral proteins with high affinity and off-target selectivity. CogMol combines adaptive pre-training of a molecular SMILES Variational Autoencoder (VAE) and an efficient multi-attribute controlled sampling scheme that uses guidance from attribute predictors trained on latent features. To generate novel and optimal drug-like molecules for unseen viral targets, CogMol leverages a protein-molecule binding affinity predictor that is trained using SMILES VAE embeddings and protein sequence embeddings learned unsupervised from a large corpus. We applied the CogMol framework to three SARS-CoV-2 target proteins: main protease, receptor-binding domain of the spike protein, and non-structural protein 9 replicase. The generated candidates are novel at both the molecular and chemical scaffold levels when compared to the training data. CogMol also includes in silico screening for assessing toxicity of parent molecules and their metabolites with a multi-task toxicity classifier, synthetic feasibility with a chemical retrosynthesis predictor, and target structure binding with docking simulations. Docking reveals favorable binding of generated molecules to the target protein structure, where 87-95% of high affinity molecules showed docking free energy < -6 kcal/mol. When compared to approved drugs, the majority of designed compounds show low predicted parent molecule and metabolite toxicity and high predicted synthetic feasibility. In summary, CogMol can handle multi-constraint design of synthesizable, low-toxic, drug-like molecules with high target specificity and selectivity, even to novel protein target sequences, and does not need target-dependent fine-tuning of the framework or target structure information.
问问这篇 Paper
智能体会读完全文。
Lune 把这篇 Paper 索引到了每一个公式,引用它的顶会 Paper 也一样。你提问,回答直接引用原文。
引用它的顶会 Paper6
- Design Principles for Generative AI ApplicationsJustin D. Weisz, Jessica He, Michael J. Muller, Gabriela Hoefer 等CHI 2024 · 被引用 221 次
- Retrieval-based Controllable Molecule GenerationZichao Wang, Weili Nie, Zhuoran Qiao, Chaowei Xiao 等ICLR 2023 · 被引用 8 次
- CombiMOTS: Combinatorial Multi-Objective Tree Search for Dual-Target Molecule GenerationThibaud Southiratn, Bonil Koo, Yijingxiu Lu, Sun KimICML 2025
- Steering Large Language Models through the DMTA Cycle: Structure-Based Drug Design via Knowledge-Driven Bi-Level Thompson SamplingXuanning Hu, Hao Tuo, Jinglong Ji, Anchen Li 等ICML 2026
- Sign Rank Limitations for Inner Product Graph DecodersSu Hyeong Lee, Qingqi Zhang, Risi KondorICML 2024
相关 Paper
- GxVAEs: Two Joint VAEs Generate Hit Molecules from Gene Expression ProfilesChen Li, Yoshihiro YamanishiAAAI 2024 · 被引用 14 次
- De novo Drug Design using Reinforcement Learning with Multiple GPT AgentsXiuyuan Hu, Guoqing Liu, Yang Zhao, Hao ZhangNeurIPS 2023 · 被引用 42 次
- Path-Aware and Structure-Preserving Generation of Synthetically Accessible MoleculesJuhwan Noh, Dae-Woong Jeong, Kiyoung Kim, Sehui Han 等ICML 2022 · 被引用 11 次
- Pocket2Mol: Efficient Molecular Sampling Based on 3D Protein PocketsXingang Peng, Shitong Luo, Jiaqi Guan, Qi Xie 等ICML 2022 · 被引用 291 次
- GenMol: A Drug Discovery Generalist with Discrete DiffusionSeul Lee, Karsten Kreis, Srimukh Prasad Veccham, Meng Liu 等ICML 2025
